Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 23.4% in April

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the target of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 8,170,000 shares, an increase of 23.4% from the March 31st total of 6,620,000 shares. Based on an average daily volume of 1,610,000 shares, the days-to-cover ratio is presently 5.1 days. Currently, 9.3% of the company's stock are short sold.

Compass Therapeutics Stock Up 3.8 %

CMPX traded up $0.07 during trading hours on Wednesday, reaching $1.76. 1,295,261 shares of the company's stock traded hands, compared to its average volume of 888,817. Compass Therapeutics has a 52-week low of $0.77 and a 52-week high of $4.08. The firm has a market capitalization of $242.69 million, a PE ratio of -4.74 and a beta of 1.40. The firm has a 50-day moving average price of $2.06 and a 200 day moving average price of $2.10.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Equities analysts predict that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Carl L. Gordon sold 3,571,428 shares of the firm's stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total transaction of $5,678,570.52. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Jonathan Anderman acquired 20,000 shares of the firm's stock in a transaction dated Monday, April 7th. The shares were bought at an average cost of $1.54 per share, with a total value of $30,800.00. Following the completion of the acquisition, the insider now directly owns 21,000 shares of the company's stock, valued at $32,340. The trade was a 2,000.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 28.50% of the company's stock.

Hedge Funds Weigh In On Compass Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Enavate Sciences GP LLC purchased a new stake in shares of Compass Therapeutics during the fourth quarter valued at about $11,293,000. Tang Capital Management LLC boosted its stake in Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock valued at $8,555,000 after acquiring an additional 4,087,005 shares in the last quarter. MPM Bioimpact LLC grew its holdings in Compass Therapeutics by 51.9% in the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock worth $12,423,000 after purchasing an additional 2,926,002 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Compass Therapeutics by 138.2% during the first quarter. SG Americas Securities LLC now owns 940,784 shares of the company's stock worth $1,787,000 after purchasing an additional 545,767 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Compass Therapeutics by 512.5% during the 4th quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company's stock worth $395,000 after buying an additional 227,864 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Jefferies Financial Group upped their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Monday, February 10th. Leerink Partnrs raised shares of Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 1st. Piper Sandler started coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They set an "overweight" rating and a $12.00 target price for the company. Wedbush reissued an "outperform" rating and issued a $8.00 price target on shares of Compass Therapeutics in a report on Tuesday, April 1st. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a research note on Monday, April 28th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Compass Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $13.38.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.